Idexx Laboratories stock hits 52-week high at $530.74

Published 24/06/2025, 21:00
Idexx Laboratories stock hits 52-week high at $530.74

Idexx Laboratories (NASDAQ:IDXX) Inc. stock reached a new 52-week high, touching $530.74 during recent trading sessions. According to InvestingPro data, the company, valued at $42.6 billion, is currently trading above its Fair Value, suggesting investors should monitor valuation levels carefully. This milestone reflects a positive trajectory for the company, which has seen its stock value increase by 7.87% over the past year. The veterinary diagnostics company has been experiencing steady growth, with revenue increasing by 5.56% in the last twelve months, driven by strong demand for its products and services in the animal healthcare sector. With an impressive financial health score rated as "GREAT" by InvestingPro, and operating with moderate debt levels, this upward trend in stock price underscores investor confidence in Idexx Laboratories’ continued expansion and innovation within the industry. InvestingPro subscribers have access to 16 additional key insights about IDXX, including detailed valuation metrics and growth indicators.

In other recent news, IDEXX Laboratories reported its first-quarter 2025 earnings, with an earnings per share (EPS) of $2.96, surpassing analyst expectations of $2.86. The company’s revenue for the quarter was $998.43 million, slightly below the anticipated $1 billion. IDEXX’s organic revenue growth was 5%, supported by the launch of new products like the IDEXX CancerDx for canine lymphoma detection. The company has also updated its full-year EPS guidance to a range of $11.93 to $12.43 per share. Analysts from Leerink Partners and BTIG have shown optimism in IDEXX’s growth, with Leerink raising the stock price target to $580 and BTIG increasing it to $545, both maintaining positive ratings. BTIG highlighted IDEXX’s ability to navigate economic challenges and improve its margins, while Leerink emphasized the company’s strong position in the veterinary diagnostics market. IDEXX’s recent product innovations and strategic management are seen as key drivers for its continued growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.